Literature DB >> 2782741

Twenty isoniazid-associated deaths in one state.

T S Moulding1, A G Redeker, G C Kanel.   

Abstract

Twenty deaths from isoniazid-associated hepatitis are known to have occurred in California over a 14-yr period in persons ranging in age from 5 to 73 yr. Because no comprehensive survey was carried out, more such deaths probably occurred. With one exception, the patients were not seen or contacted monthly throughout the course of treatment. However, in 16 patients where the information was known, eight were seen by a member of the group giving the isoniazid (INH) within 30 days prior to the patients presenting with hepatitis. In 12 of 17 cases, symptoms were present for 7 days or more before the patient presented for medical care. In at least 35% of cases where the information was known, a management error occurred, usually failing to immediately stop INH when the patient presented with symptoms. The duration of treatment before hepatitis developed varied from 9 to 53 wk. Four of the 20 patients had cholelithiasis or a history of cholelithiasis. With one possible exception, no excessive alcohol use was noted. Concomitant acetaminophen, barbiturate, and tetracycline use occurred in several cases. There were no deaths in Orientals. Sixteen of the 20 deaths occurred in women who had started to receive INH between the ages of 15 and 55. Four of these women began receiving INH during pregnancy and continued it postpartum. Eight deaths occurred in persons starting INH before 35 yr of age. The continued occurrence of INH-associated deaths suggests that indications and precautions for INH preventive treatment be carefully reconsidered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782741     DOI: 10.1164/ajrccm/140.3.700

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

2.  Pregnancy does not mean that patients with tuberculosis must stop treatment.

Authors:  G Bothamley; W Elston
Journal:  BMJ       Date:  1999-05-08

3.  Treatment strategies in the prevention of tuberculosis.

Authors:  T L Petty
Journal:  West J Med       Date:  1992-10

4.  Hepatotoxicity of antituberculosis drugs.

Authors:  J Devlin; D C Hutchison; S Fitt; J Wendon; R Williams
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

5.  Isoniazid toxicity in a 5-year-old boy.

Authors:  Michelle Science; Shinya Ito; Ian Kitai
Journal:  CMAJ       Date:  2013-05-13       Impact factor: 8.262

6.  Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.

Authors:  A C Anand; A K Seth; M Paul; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Isoniazid hepatotoxicity requiring liver transplantation.

Authors:  Edward Sheen; Robert J Huang; Lindsay A Uribe; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

Review 8.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

9.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

10.  Short-course therapy for tuberculosis in infants and children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1994-04-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.